X

Trial Profile

A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced With Cemiplimab (LIBTAYO) in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 03 Oct 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs 2 deoxythioguanosine (Primary) ; Cemiplimab (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions; Therapeutic Use
Acronyms THIO-101
Sponsors MAIA Biotechnology

Most Recent Events

10 Sep 2024 According to a MAIA Biotechnology media release, company expects to release full efficacy results of THIO-101 this year.
10 Sep 2024 Results presented in a MAIA Biotechnology media release.
10 Sep 2024 According to a MAIA Biotechnology media release, company today Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com